|
 |
Diseases and Conditions
The nonclinical drug candidates that Akros Pharma takes into clinical development
come out of the research conducted by the Central Pharmaceutical Research Institute
(CPRI) of JT Pharmaceuticals in Osaka, Japan. The current development focus for Akros
reflects the research focus at CPRI.
Currently, CPRI and Akros are working to develop new therapeutics for the following
disease states:
|
DISEASE
STATE |
MECHANISTIC
APPROACH TO DISEASE TREATMENT |
| A |
Dyslipidemia |
Improve imbalances in blood lipids (decrease low-density lipids
and increase high density lipids) by inhibiting CETP (Cholesteryl Ester Transfer
Protein) |
| B |
Obesity |
Reduce oral absorption of dietary cholesterol and triglycerides
by inhibiting i-MTP (intestinal Microsomal Triglyceride Transfer Protein) |
| C |
Osteoporosis |
Stimulate bone growth through release of parathyroid hormone
(PTH) by Calcium-sensing receptor antagonism |
| D |
Diabetes |
Decrease insulin resistance by inhibiting protein tyrosine
phosphatase-1b (PTP1b), an enzyme involved in the regulation of insulin signaling |
©2007 Akros Pharma Inc. All rights reserved.
|
